This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Capitol Hill Briefing On Value Of Clinical Laboratory Testing

 "From Protecting Public Health and Fighting Disease to Saving Health Care Dollars" -- Briefing Explores Policy Issues Surrounding Lab Testing

To Take Place Noon, Feb  11, 2013 at Capitol Hill Visitors Center

Media must RSVP by Noon ET, Feb 8, 2013 for Admittance

WASHINGTON, Feb. 4, 2013 /PRNewswire-USNewswire/ -- The foundation for 70% of physician decision-making, clinical laboratory tests are one of the most critical elements in preventing chronic illness, curtailing epidemics, and improving cancer care.

At the same time, clinical lab tests are making the U.S. health care delivery system more cost-effective.

On February 11, Kenneth Sisco, MD, Ph.D., medical director of Quest Diagnostics, will explore this topic at a Capitol Hill briefing for Congressional staff, members of the House and Senate, health care and patient organizations, and the news media in the visitors center of the U.S. Capitol building. The briefing is sponsored by "Results for Life," the educational arm of the American Clinical Laboratory Association (ACLA).

At the briefing, "Clinical Laboratory Testing:  Providing Critical Evidence for Diagnosis and Treatment," Dr. Sisco will explain what clinical laboratory tests are and why they are so crucial to improving patient health and utilization of health care resources.

Alan Mertz, ACLA President, will discuss health policy issues before Congress and federal agencies that could affect innovation and the availability of clinical laboratory testing.

Here are some examples that are expected to be discussed at the briefing:
  • Clinical lab tests are essential to curtailing chronic disease, which accounts for 75% of all health care costs in the U.S. For example, the hemoglobin A1c test can diagnose diabetes in early stages when people can take steps to prevent or delay full-blown diabetes. The test costs about $13.50 – as opposed to $27,000 for an amputation or the $28,000 for a heart attack that can result from complications of diabetes.
  • Clinical lab testing and HIV drugs have dramatically reduced HIV deaths by enabling physicians to decide the best drug treatment and dosage for the individual.
  • Genetic tests that target treatment to the genetic fingerprint of the individual are opening up new vistas in cancer care. For 40% of patients with metastatic colorectal cancer, standard cancer drugs will not work because patients have a genetic mutation called KRAS. A genetic test can identify this mutation, allowing physicians to avoid the drugs that will not help such patients and that have serious and painful side effects. Patients can get started on a more effective therapy sooner. The projected savings by avoiding the use of this drug in patients who wouldn't benefit from it range from $100 million to $600 million per year, according to two studies.

The briefing will begin at noon ET in the U.S. Capitol Visitors Center, Congressional Meeting Room North, East Capitol Street NE & First Street.

RSVP's are essential. Members of the media should contact:, or (202) 637-9466 by noon on Fri., Feb. 8 .

The American Clinical Laboratory Association is a non-profit group representing the nation's clinical  laboratories. Results for Life, the group's educational campaign, focuses on the value of laboratory medicine. See

Contact: Ron Geigle, 202-461-2246 or Helen Pettay, 910-795-1202

SOURCE American Clinical Laboratory Association

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.31%
FB $102.01 0.10%
GOOG $682.40 -0.10%
TSLA $151.04 0.38%
YHOO $27.04 1.05%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs